Therapeutic advances in urology · 2026
Endoscopic management of vesicourethral anastomotic stenosis after radical prostatectomy: final outcomes defined by urethral patency and continence.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Andrzej Skrzypczyk Michał, Łukasz Białek, Marta Rydzińska, Piotr Gwara, Jakub Dobruch
Аннотация
BACKGROUND: Vesicourethral anastomotic stenosis (VUAS) remains a challenging sequela of radical prostatectomy (RP).
OBJECTIVES: To evaluate endoscopic outcomes in men with VUAS using a patient-centred composite endpoint of concurrent urethral patency and continence.
DESIGN: Retrospective, single-centre consecutive case series.
METHODS: We analysed 60 consecutive men treated endoscopically for VUAS (2014-2023). Primary endpoints were urethral patency (passage of a 20F catheter at 6-month follow-up) and continence (0-1 pad/day at last follow-up; for men with an artificial urinary sphincter (AUS), assessed after device activation). Secondary endpoints included AUS implantation and complications. Subgroup comparisons by prior pelvic radiotherapy (RTx) were performed using Fisher's exact and Mann-Whitney tests.
RESULTS: Median follow-up was 40 months. Patency was achieved in 45/60 (75%). Continence was achieved in 22/60 (36.7%): 5 men remained continent without AUS and 17 became continent after AUS; 4/21 AUS required explant for erosion. Composite success (patency plus continence) occurred in 20/60 (33.3%). Prior RTx was not significantly associated with patency, continence, composite success, or AUS implantation. Three men required urinary diversion for pubic bone fistulation and three were diagnosed with bladder cancer (no AUS implanted). Seventeen patients declined AUS despite persistent stress urinary incontinence.
CONCLUSION: Endoscopic treatment restores urethral patency in most men with post-RP VUAS, but the final patient-centred outcome of simultaneous patency and continence is achieved in one-third. These data may support shared decision-making regarding expectations and staged continence surgery.
TRIAL REGISTRATION: Not applicable.
OBJECTIVES: To evaluate endoscopic outcomes in men with VUAS using a patient-centred composite endpoint of concurrent urethral patency and continence.
DESIGN: Retrospective, single-centre consecutive case series.
METHODS: We analysed 60 consecutive men treated endoscopically for VUAS (2014-2023). Primary endpoints were urethral patency (passage of a 20F catheter at 6-month follow-up) and continence (0-1 pad/day at last follow-up; for men with an artificial urinary sphincter (AUS), assessed after device activation). Secondary endpoints included AUS implantation and complications. Subgroup comparisons by prior pelvic radiotherapy (RTx) were performed using Fisher's exact and Mann-Whitney tests.
RESULTS: Median follow-up was 40 months. Patency was achieved in 45/60 (75%). Continence was achieved in 22/60 (36.7%): 5 men remained continent without AUS and 17 became continent after AUS; 4/21 AUS required explant for erosion. Composite success (patency plus continence) occurred in 20/60 (33.3%). Prior RTx was not significantly associated with patency, continence, composite success, or AUS implantation. Three men required urinary diversion for pubic bone fistulation and three were diagnosed with bladder cancer (no AUS implanted). Seventeen patients declined AUS despite persistent stress urinary incontinence.
CONCLUSION: Endoscopic treatment restores urethral patency in most men with post-RP VUAS, but the final patient-centred outcome of simultaneous patency and continence is achieved in one-third. These data may support shared decision-making regarding expectations and staged continence surgery.
TRIAL REGISTRATION: Not applicable.